Additionally, NSCLC patients without baseline brain or liver metastases significantly benefit from anti-PD-1/PD-L1 therapies, whereas no differences existed for those patients with baseline brain or liver metastases [79,182]. Here, CD274 is linked to non-small cell lung carcinoma.